Travere Therapeutics Inc
NASDAQ:TVTX
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
5.26
19.85
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Travere Therapeutics Inc
Gross Profit
Travere Therapeutics Inc
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Travere Therapeutics Inc
NASDAQ:TVTX
|
Gross Profit
$193.7m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
30%
|
||
Abbvie Inc
NYSE:ABBV
|
Gross Profit
$37.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
||
Gilead Sciences Inc
NASDAQ:GILD
|
Gross Profit
$22B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
||
Amgen Inc
NASDAQ:AMGN
|
Gross Profit
$19.7B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
2%
|
||
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Gross Profit
$9.2B
|
CAGR 3-Years
13%
|
CAGR 5-Years
24%
|
CAGR 10-Years
29%
|
||
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Gross Profit
$12B
|
CAGR 3-Years
1%
|
CAGR 5-Years
15%
|
CAGR 10-Years
17%
|
Travere Therapeutics Inc
Glance View
Travere Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 310 full-time employees. The company went IPO on 2003-07-23. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its products include Chenodal (chenodiol tablets), Cholbam (cholic acid capsules), and Thiola and Thiola EC (tiopronin tablets). Chenodal, which is for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Cholbam, which is for the treatment of bile acid synthesis disorders due to single enzyme defects. Thiola and Thiola EC, which are for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. The firm's clinical program Sparsentan (RE-021), is an investigational product candidate with a dual mechanism of action, selective endothelin receptor antagonist (ERA), with in vitro selectivity toward endothelin receptor type A, and a potent angiotensin receptor blocker.
See Also
What is Travere Therapeutics Inc's Gross Profit?
Gross Profit
193.7m
USD
Based on the financial report for Sep 30, 2024, Travere Therapeutics Inc's Gross Profit amounts to 193.7m USD.
What is Travere Therapeutics Inc's Gross Profit growth rate?
Gross Profit CAGR 10Y
30%
Over the last year, the Gross Profit growth was 31%. The average annual Gross Profit growth rates for Travere Therapeutics Inc have been -3% over the past three years , 3% over the past five years , and 30% over the past ten years .